citric acid, anhydrous and Coronary Disease studies

Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.

Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.

Research Excerpts

Excerpt	Relevance	Reference
"We randomized 70 acute coronary syndrome patients undergoing percutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban at doses used in the Evaluation of Platelet IIb/IIIa Inhibitor for STENTing (EPISTENT), Platelet glycoprotein IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM-PLUS)/Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) trials, respectively."	9.10	Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an ( Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP, 2002)
" We therefore studied the effects of diltiazem and reduced serum ionized calcium on ventricular fibrillation (VF) in a reversible ligation model."	7.66	The effects of diltiazem and reduced serum ionized calcium on ischemic ventricular fibrillation in the dog. ( Baim, DS; Brett, P; Bristow, MR; Clusin, WT; Harrison, DC; Jaillon, P; Schroeder, JS, 1982)
"We randomized 70 acute coronary syndrome patients undergoing percutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban at doses used in the Evaluation of Platelet IIb/IIIa Inhibitor for STENTing (EPISTENT), Platelet glycoprotein IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM-PLUS)/Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) trials, respectively."	5.10	Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an ( Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP, 2002)
"Although hydralazine is a commonly prescribed antihypertensive agent, reports of acute human poisoning are uncommon."	3.68	Acute hydralazine overdose: marked ECG abnormalities in a young adult. ( Ferguson, DB; Smith, BA, 1992)
" We therefore studied the effects of diltiazem and reduced serum ionized calcium on ventricular fibrillation (VF) in a reversible ligation model."	3.66	The effects of diltiazem and reduced serum ionized calcium on ischemic ventricular fibrillation in the dog. ( Baim, DS; Brett, P; Bristow, MR; Clusin, WT; Harrison, DC; Jaillon, P; Schroeder, JS, 1982)
"Ranolazine was given as an intravenous bolus followed by continuous infusion; the mean total dose was 32."	1.30	Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. ( Bagger, JP; Bøtker, HE; Nielsen, TT; Thomassen, A, 1997)
"This study was designed to review the incidence of adverse events during nearly 20,000 apheresis procedures over a 4-year period in a hospital-based program."	1.30	Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program. ( Baorto, D; Despotis, GJ; Dynis, M; Goodnough, LT; Spitznagel, E, 1999)

Research

Studies (16)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Atrial Fibrillation

Timeframe	Studies, this research(%)	All Research%
pre-1990	11 (68.75)	18.7374
1990's	3 (18.75)	18.2507
2000's	1 (6.25)	29.6817
2010's	1 (6.25)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Uitte de Willige, S	1
Keane, FM	1
Bowen, DG	1
Malfliet, JJMC	1
Zhang, HE	1
Maneck, B	1
McCaughan, GW	1
Leebeek, FWG	1
Rijken, DC	1
Gorrell, MD	1
Batchelor, WB	1
Tolleson, TR	1
Huang, Y	1
Larsen, RL	1
Mantell, RM	1
Dillard, P	1
Davidian, M	1
Zhang, D	1
Cantor, WJ	1
Sketch, MH	1
Ohman, EM	1
Zidar, JP	1
Gretler, D	1
DiBattiste, PM	1
Tcheng, JE	1
Califf, RM	1
Harrington, RA	1
NORDIO, S	1
Thomassen, AR	1
Nielsen, TT	3
Bagger, JP	3
Henningsen, P	2
Valles, J	1
Aznar, J	1
Santos, MT	1
Fernandez, MA	1
Clusin, WT	1
Bristow, MR	1
Baim, DS	1
Schroeder, JS	1
Jaillon, P	1
Brett, P	1
Harrison, DC	1
Bøtker, HE	1
Thomassen, A	2
Despotis, GJ	1
Goodnough, LT	1
Dynis, M	1
Baorto, D	1
Spitznagel, E	1
Smith, BA	1
Ferguson, DB	1
Allen, BS	3
Okamoto, F	2
Buckberg, GD	3
Bugyi, H	2
Young, H	2
Leaf, J	2
Beyersdorf, F	1
Sjostrand, F	1
Maloney, JV	1
Schwaiger, M	1
Yeatman, L	1
Tillisch, J	1
Kawata, N	1
Messenger, J	1
Lee, C	1
Nishimura, T	1
Kihara, K	1
Shimonagata, T	1
Uehara, T	1
Hayashida, K	1
Hayashi, M	1
Oka, H	1
Matsuo, H	1
Park, YD	1
Kitoh, Y	1
Leijala, MA	1
Dumont, L	1
Stanley, P	1
Chartrand, C	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827]	Phase 3	865 participants (Actual)	Interventional	2005-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay

ICU Stay

Number of Participants With Perioperative Myocardial Infarction, Postoperative Heart Failure or Postoperative Mortality

Number of Participants With Postoperative Stroke < 24 Hours

Intervention	Participants (Count of Participants)
Intravenous Glutamate	147
Saline Infusion	152

Intervention	hours (Median)
Intravenous Glutamate	21
Saline Infusion	21

Intervention	Participants (Count of Participants)
Intravenous Glutamate	31
Saline Infusion	25

Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours

Postoperative Hemodynamic State in Patients With Severely Reduced Left Ventricular Ejection Fraction (LVEF<0.40)

Intervention	Participants (Count of Participants)
Intravenous Glutamate	4
Saline Infusion	6

Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery

Postoperative Renal Function

Intervention	Participants (Count of Participants)
Intravenous Glutamate	1
Saline Infusion	5

maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days

Severe Circulatory Failure in CCS Class IV Patients

Intervention	µmol/L (Mean)
Intravenous Glutamate	106
Saline Infusion	106

Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days

Degree of Perioperative Myocardial Injury

Intervention	Participants (Count of Participants)
Intravenous Glutamate	3
Saline Infusion	16

p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative

Postoperative Hemodynamic State

Intervention	µg/L (Median)
	CK-MB day 1	Troponin-T day 3
Intravenous Glutamate	14	0.27
Saline Infusion	14	0.24

Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU

Intervention	percentage of saturated hemoglobin (Mean)
	SvO2 at weaning from CPB	SvO2 on arrival to ICU
Intravenous Glutamate	72.0	65.0
Saline Infusion	72.2	64.9

Article	Year
Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. PloS one, 2017, Volume: 12, Issue:6 Topics: Adolescent; Adult; Anticoagulants; Biomarkers; Body Mass Index; Case-Control Studies; Citric Acid; C	2017
[Modern aspects of calcium and phosphorus metabolism in childhood; relation to citric acid metabolism, acid-base equilibrium, renal function, etc]. Minerva pediatrica, 1957, Sep-15, Volume: 9, Issue:37 Topics: Acid-Base Equilibrium; Calcium; Citrates; Citric Acid; Coronary Disease; Heart; Humans; Phosphorus;	1957
Myocardial exchanges of glutamate, alanine and citrate in controls and patients with coronary artery disease. Clinical science (London, England : 1979), 1983, Volume: 64, Issue:1 Topics: Aged; Alanine; Cardiac Pacing, Artificial; Citrates; Citric Acid; Coronary Disease; Fatty Acids, Non	1983
Elevated lipid peroxide levels in platelets of chronic ischemic heart disease patients. Thrombosis research, 1982, Sep-01, Volume: 27, Issue:5 Topics: Anticoagulants; Aspirin; Blood Platelets; Chronic Disease; Citrates; Citric Acid; Coronary Disease;	1982
The effects of diltiazem and reduced serum ionized calcium on ischemic ventricular fibrillation in the dog. Circulation research, 1982, Volume: 50, Issue:4 Topics: Animals; Benzazepines; Calcium; Citrates; Citric Acid; Coronary Circulation; Coronary Disease; Dilti	1982
Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. Cardiovascular drugs and therapy, 1997, Volume: 11, Issue:3 Topics: Acetanilides; Aged; Alanine; Angina Pectoris; Blood Pressure; Citric Acid; Coronary Circulation; Cor	1997
Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program. Vox sanguinis, 1999, Volume: 77, Issue:1 Topics: Adult; Blood Donors; Cardiovascular Diseases; Citric Acid; Coronary Disease; Demography; Drug Overdo	1999
Acute hydralazine overdose: marked ECG abnormalities in a young adult. Annals of emergency medicine, 1992, Volume: 21, Issue:3 Topics: Adult; Alcoholic Intoxication; Antacids; Cardiopulmonary Resuscitation; Charcoal; Citrates; Citric A	1992
Cardiac metabolic and hemodynamic effects of insulin in patients with coronary artery disease. Diabetes, 1989, Volume: 38, Issue:9 Topics: Alanine; Blood Glucose; Cardiac Catheterization; Citrates; Citric Acid; Coronary Disease; Drug Evalu	1989
Immediate functional recovery after six hours of regional ischemia by careful control of conditions of reperfusion and composition of reperfusate. The Journal of thoracic and cardiovascular surgery, 1986, Volume: 92, Issue:3 Pt 2 Topics: Animals; Aspartic Acid; Calcium; Citrates; Citric Acid; Coronary Circulation; Coronary Disease; Dogs	1986
Early recovery of regional wall motion in patients following surgical revascularization after eight hours of acute coronary occlusion. The Journal of thoracic and cardiovascular surgery, 1986, Volume: 92, Issue:3 Pt 2 Topics: Aspartic Acid; Citrates; Citric Acid; Coronary Circulation; Coronary Disease; Glucose; Glutamates; G	1986
[Detection of cardiac and arterial thrombi by 67Ga-DFO-fibrinogen scintigraphy]. Kokyu to junkan. Respiration & circulation, 1988, Volume: 36, Issue:8 Topics: Adult; Aged; Citrates; Citric Acid; Coronary Disease; Coronary Thrombosis; Female; Fibrinogen; Human	1988
Reperfusate composition: interaction of marked hyperglycemia and marked hyperosmolarity in allowing immediate contractile recovery after four hours of regional ischemia. The Journal of thoracic and cardiovascular surgery, 1986, Volume: 92, Issue:3 Pt 2 Topics: Animals; Aspartic Acid; Citrates; Citric Acid; Coenzymes; Coronary Circulation; Coronary Disease; Di	1986
Peroperative myocardial ischemia and citrate administration: cardiovascular adaptability in conscious dogs. European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 1985, Volume: 17, Issue:4 Topics: Adaptation, Physiological; Animals; Anticoagulants; Blood Preservation; Citrates; Citric Acid; Coron	1985

citric acid, anhydrous and Coronary Disease